Institute Curie (20240247318). METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS simplified abstract
Contents
- 1 METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Key Features and Innovation
- 1.6 Potential Applications
- 1.7 Problems Solved
- 1.8 Benefits
- 1.9 Commercial Applications
- 1.10 Questions about DNA Homologous Recombination Pathway Detection
- 1.11 Original Abstract Submitted
METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS
Organization Name
Inventor(s)
Marc-Henri Stern of Paris (FR)
Tatiana Popova of La Varenne Saint Hilaire (FR)
METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240247318 titled 'METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS
Simplified Explanation
The patent application discusses methods for detecting inactivation of the DNA homologous recombination pathway in a patient, specifically focusing on detecting BRCA1 inactivation.
Key Features and Innovation
- Detection methods for inactivation of the DNA homologous recombination pathway
- Focus on detecting BRCA1 inactivation in particular
Potential Applications
The technology can be used in cancer diagnostics and personalized medicine to identify patients who may benefit from specific treatments based on their DNA repair pathway status.
Problems Solved
- Identifying patients with inactivated DNA repair pathways
- Targeting treatments based on individual genetic profiles
Benefits
- Personalized treatment options for cancer patients
- Improved accuracy in identifying patients who may benefit from specific therapies
Commercial Applications
The technology has potential applications in the pharmaceutical industry for developing targeted cancer therapies and in clinical settings for guiding treatment decisions based on genetic information.
Questions about DNA Homologous Recombination Pathway Detection
How can the detection of DNA homologous recombination pathway inactivation impact cancer treatment decisions?
The detection of DNA homologous recombination pathway inactivation can help identify patients who may benefit from specific treatments, leading to more personalized and effective cancer therapies.
What are the implications of detecting BRCA1 inactivation in cancer patients?
Detecting BRCA1 inactivation can guide treatment decisions, allowing for targeted therapies that may be more effective in patients with this specific genetic alteration.
Original Abstract Submitted
the invention relates to methods for detecting inactivation of the dna homologous recombination pathway in a patient, and in particular for detecting brca1 inactivation.
